Enliven Therapeutics Inc
ELVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.27B
Close$
$1.74
97.1% downside
Current Fair Value
97.1% downsideOvervalued by 97.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.27 Billion |
|---|---|
| Enterprise Value | $4.14 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.83 |
| Beta | 0.24 |
| Outstanding Shares | 66,171,581 |
Return
| Return on Equity | -11.83% |
|---|---|
| Return on Assets | -11.64% |
| Return on Invested Capital | -12.81% |
Valuation & Multiples
| P/E Ratio | -36.48 |
|---|---|
| PEG | -129.25 |
| Price to Sales | - |
| Price to Book Ratio | 4.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -36.08 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6484▲ 33.01% |
|---|---|
| Total Calls | 184,000▼ 85.08% |
| Total Puts | 119,300▼ 69.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 128.23%▲ 18.13% |
|---|---|
| Total Invested | $4.08B▲ 67.91% |
| Investors Holding | 218▲ 38.00% |
ESG Score
No data
About Enliven Therapeutics Inc
41 employees